IFNG and neoplasm: MSA-2, in combination with YM101, a bispecific antibody targeting TGF-β and PD-L1, inhibits tumor growth in EMT-6 mice and increases CD3-CD49b+, Ki67+, IFN-γ+, GZMB+, and TNF-α+ NK ratios 184.